Tania Z. Dickson

Analysis of Metabolic Parameters as Predictors of Risk in the RENAAL Study

Gerald B. Appel, Jai Radhakrishnan, Morrell M. Avram et al. · Diabetes Care · 2003 · 109 citations · Full text

Medicine, Nephrology, Pharmacotherapy +14

Renin Angiotensin Aldosterone System Blockade and Renal Disease in Patients With Type 2 Diabetes

Juliana C.N. Chan, Nelson M.S. Wat, Wing‐Yee So et al. · Diabetes Care · 2004 · 80 citations

Medicine, Pharmacology, Pharmacotherapy +17

Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study

Geoffrey Boner, M. E. Cooper, K. A. McCarroll et al. · Diabetologia · 2005 · 44 citations

Medicine, Cardiology, Physiology +14

Importance of Baseline Distribution of Proteinuria in Renal Outcomes Trials: Lessons from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study

Zhongxin Zhang, Shahnaz Shahinfar, William F. Keane et al. · Journal of the American Society of Nephrology · 2005 · 39 citations

Pharmacy, Biostatistics, Pharmacotherapy +14

Losartan in patients with type 2 diabetes and proteinuria: Observations from the RENAAL Study

Shahnaz Shahinfar, Tania Z. Dickson, Tultul Ahmed et al. · Kidney International · 2002 · 33 citations

Medicine, Endocrinology, Nephrology +12